Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2

Status

Completed 2Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia 1High Risk Myeloid Malignancies 1Hematologic Neoplasms 1Graft vs Host Disease 1

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 125Radiotherapy 119Cisplatin 111Carboplatin 111pembrolizumab 109Nivolumab 106Docetaxel 90Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Bevacizumab 64Fluorouracil 63Etoposide 63Oxaliplatin 62Filgrastim 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58Capecitabine 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 53Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × Transplantation Conditioning × Clear all
NCT04990323 2026-03-24

US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies

ExCellThera inc.

Phase 1/2 Completed
13 enrolled

High Risk Myeloid Malignancies

NCT01379209 2019-10-23

Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)

Regimmune Corporation

Phase 1/2 Completed
68 enrolled
MyeloidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Myelodysplastic Syndromes, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡